Introduction
Biliary tract cancers (BTCs) are relatively poorly understood rare malignancies with an increasing prevalence reported in the last few decades [1, 2] . The incidence varies hugely with an agestandardised rate (ASR) of 3.46/100,000 in males and 2.99/100,000 in females in England & Wales [3] , whereas in Thailand, the ASR is
Methodology
Biomedical electronic databases, including EMBASE, MED-LINE, PUBMED, and ClinicalTrials.gov were interrogated for all full manuscripts and conference abstracts written in the English language (at least the abstract) and published up to January 2018 using the keywords 'biliary tract cancer', 'immunotherapy', and 'immune checkpoint inhibitors'.
Role of Immune Cells and Their Function in the Tumour Microenvironment of BTC
The role of the immune environment in the carcinogenic process has been studied in depth, and a number of hypotheses have been proposed. One of these is 'cancer immunoediting', encompassing 3 steps leading to carcinogenesis: elimination, whereby immune surveillance abolishes nascent transmuted cells; equilibrium, whereby cancer cells which have the capacity to overcome the immune surveillance coexist in harmony with the immune system; and lastly escape, whereby tumour cells multiply and expand exponentially in an immunocompetent host [19] . The host immunity constitutes a plethora of immune cells and interacts with the cancer through its surroundings, the 'tumour microenvironment' (TME) [20] ; a complex structure that constitutes the immune infiltrate, stromal cells, extracellular matrix, and tumour vasculature [21] . The immune-infiltrating cells include cluster of differentiation 4 + (CD4 + ) T cells, CD8 + T cells, tumour-infiltrating lymphocytes (TILs), CD66b
+ neutrophils, and interleukin-17 + T-helper (IL17 + T H ) cells, to name a few. The intensities of these various immune infiltrates within the TME in patients with BTC were evaluated in a meta-analysis. This analysis reported a positive association of OS with high levels of expression of CD4 + T cells, CD8 + T cells, TILs, major histocompatibility complex-I (MHC-I)-presenting cells, and natural killer group 2, member D (NKG2D) cells (hazard ratio (HR) 0.52, p < 0.00001). In contrast to this, high levels of CD66b + neutrophils and PD-1 + /CD8 + TILs were negatively associated with OS (HR 1.79, p < 0.00001) in the same patient population [22] .
Another study of 110 patients with resected stage I-IV GBC reported high CD4 + T cell count in 51% (n = 23/45) of cases, high CD8 + T cells in 37.8% (n = 17/45), high natural killer cells (NKC) in 33.3% (n = 15/45), and high dendritic cells in 48.9% (n = 22/45). A favourable prognosis was seen with high levels of CD4 + T cells (p = 0.0033), CD8 + T cells (p = 0.0081), and dendritic cells (p = 0.04) [23] .
The above studies highlight the relationship between immune cells and OS.
Role of Immune Cells in the Phasic Process of Carcinogenesis in BTC
Further to the studies on the correlation of patients' clinical outcomes with various components of the immune system, a study evaluated the role of these immune cells in the cascade that leads to carcinogenesis. Levels of immune infiltrate cells were measured in 375 surgically resected patients with BTC (stages I-IV), including 157 with intrahepatic cancer (IHC), 149 with extrahepatic cancer (EHC), and 69 with GBC; differences between these levels as precancerous lesions developed into tumours were also studied [24] . CD8 + T cells (48.4%) were more common than CD4 + T cells (36.3%), B lymphocytes were low (1.4%), macrophages were high (77.6%), and NKC were low (19.1%). Interestingly, CD4 + T cells, CD8 + T cells, B lymphocytes, regulatory T cells, NKC, and mast cells were higher in precancerous lesions (e.g., biliary intraepithelial neoplasia grade 3, Bil-IN III), and their numbers gradually decreased as the cells transformed into cancerous lesions and then metastasised [24] ; in contrast, macrophage numbers gradually increased during this process. This study also reported a positive correlation of OS with the presence of CD4 + T cells (p = 0.002), CD8 + T cells (p = 0.015), total regulatory T lymphocytes (p = 0.018), and total B lymphocytes (p = 0.032) [24] . The above work highlights the stepwise change in the immune microenvironment in various stages of carcinogenesis of BTC.
Role of Macrophages and Fibroblasts in the Carcinogenesis of BTC
In an animal model, the role of tumour-associated macrophages (TAMs) and cancer-associated fibroblasts(CAFs) in the carcinogenesis of CCA was evaluated [25] . This study reported an increasing intensity of TAMs as the lesions changed from hyperplastic to dysplastic and, eventually, to CCA. In human cell lines, markers of TAMs (CD68 and CD163) were seen in 53 and 51% of cases, respectively [25] . Thus, fibroblasts and macrophages appear to be numerically prevalent, and may have an important functional role in carcinogenesis.
Role of Inflammatory Biomarkers in BTC
IL-6 has been implicated as a facilitator towards neoplastic growth due to its ability to block apoptosis of cells during inflammation [26] . A study evaluating the role of IL-6 and its association with epithelial mesenchymal transition (EMT)-associated proteins (twist, vimentin, and e-cadherin) in 20 cholecystectomy samples from patients with GBC [27] reported a high frequency of IL-6 in 40% (8/20) , twist in 20% (4/20) , and vimentin in 70% (14/20) . Patients whose tumours had increased levels of IL-6 and twist and low levels of e-cadherin had a worse OS.
Blood IL-6 levels were assessed in another study where 60 patients with hepatic disease were included (CCA n = 15, hepatocellular carcinoma (HCC) n = 14, colorectal cancer (CRC) hepatic metastasis n = 26, and benign biliary tract disease n = 5). All 15 (100%) patients with CCA had elevated levels of IL-6. Moreover, levels were higher in CCA patients when compared to patients with other cancer types [28] . There was also a correlation between tumour burden and IL-6 levels (the higher the tumour burden, the greater the levels of IL-6) in CCA (p = 0.04), and 2 weeks after curative resection IL-6 dropped to undetectable levels in these patients [28] . Further studies are needed to evaluate the role of IL-6 as a biomarker in BTC.
Another marker, the neutrophil lymphocyte ratio (NLR), was analysed retrospectively in 864 patients with all stages of BTC to evaluate its prognostic value. In patients with NLR 3.0, median OS was 12.0 months versus 21.6 months in patients with NLR < 3.0 (adjusted HR 1.26, p = 0.01) [29] . The derived neutrophil-to-lymphocyte ratio (dNLR; used when the absolute lymphocyte count is not available) was studied as a prognostic marker in 462 patients with advanced BTC from the combined data of 2 clinical studies (ABC-02 and BT22). Cisplatin/gemcitabine-treated patients with low dNLR had a median OS of 10.6 months versus 6.4 months in the high dNLR group ( 3) (HR 1.62, p 0.001). The adjusted HR for progression-free survival (PFS) was 1.4 for the low dNLR group [30] .
The above work demonstrates an adverse association of clinical outcomes with high NLR, consistent with findings in other solid malignancies [31] . This inexpensive, readily available biomarker may warrant further prospective evaluation and ultimately validation.
Role of Stimulatory Immunotherapies Such as Vaccines in BTC
The host immune response to cancer is induced by the release of cancer-associated antigens by cancer cells, which are presented through antigen-presenting cells. Some of these cancer-associated antigens have been evaluated as cancer vaccines in different cancers. In BTC, these include Wilms' tumour gene-1 antigen (WT1) and Mucin-1 (MUC-1) [32, 33] .
WT1 was analysed in 494 samples from patients with different tumour types (BTC n = 23). The authors reported that polyclonal (C-19) WT1 antigen was expressed in 80% (n = 15/22) of patients [34] . Due to this high frequency, a Japanese phase I study of 16 patients with advanced BTC evaluated the toxicity, safety, and optimum dose of the WT1 vaccine given in combination with gemcitabine. There were no dose-limiting toxicities for the combination, and the median OS in BTC was 9.5 months [35] .
MUC-1, also found to be expressed in BTC, is a glycoprotein associated with cell membranes. A study analysed 32 surgical specimens of IHC and 7 of bile duct cystadenocarcinoma for the presence of MUC-1. It was negative (0%, n = 0/7) in bile duct cystadenocarcinoma, 50% (n = 6/12) in perihilar IHC, and 85% (n = 17/20) in mass-forming IHC [36] . A phase I study accrued patients (BTC n = 3, and pancreatic cancer (PC) n = 6) to assess the efficacy of the MUC-1 vaccine; of these, 1 patient developed stable disease [37] . A MUC-1 peptide-loaded dendritic cell vaccine was evaluated in the adjuvant setting in a phase I/II study of 12 cases of surgically-resected PC and BTC. At the end of the study period, 4/12 patients were still alive; the median OS was reported as 26 months [38] . This study is unique as it looked at the use of vaccines in the adjuvant setting rather than in the metastatic disease group.
Further to WT1 and MUC-1 vaccines, other cancer vaccines were assessed in a phase I study which accrued 9 patients with advanced IHC, EHC, and GBC, refractory to standard chemotherapy, to evaluate the simultaneous administration of 3 cancer peptide vaccines, i.e., cell division cycle associated-1 (CDCA1), cadherin-3 (CDH3), and kinesin family member 20A (KIF20A). The authors reported stable disease after the 8th vaccination (1.84 months) in 4 patients, whereas 4 patients developed progressive disease. This study allowed patients to continue treatment despite disease progression, and these patients eventually developed stable disease on long-term vaccines. The median OS was 9.7 months. Whilst modest, an OS of 9.7 months following chemotherapy in refractory disease warrants further evaluation in phase II/III studies [39] .
Role of Cytokines as an Immunotherapy in BTC
Apart from the evaluation of vaccines in BTC, the use of IL-2 as an immunotherapy was analysed in a study alongside 13-cis-retinoic acid (RA) in 54 patients with a diagnosis of inoperable or locally advanced PC and BTC. All patients were initially treated with 3 cycles of gemcitabine and cisplatin. Then, patients with stable disease (n = 38) went on to consolidation chemo-radiotherapy with capecitabine. Of these, 14 patients (n = 7 PC, n = 7 BTC) who continued to have stable disease went on to receive IL-2 and RA. After a median follow up of 27.5 months, 3 patients had achieved complete radiological responses and 11 had partial responses. After 4 years, 2 of 7 patients with PC and 3 of 7 patients with BTC were still alive; the median PFS was 16.2 months and the median OS was not reached at the last follow up (27.5 months) [40] .
Although promising, a major limitation of this study was that the patients with rapidly progressive disease were filtered out in the early steps. Therefore, patients who went on to receive the immunotherapy might have been those with a more favourable underlying biology.
Role of Adoptive Cell Therapy in BTC
Adoptive cell therapy (ACT) refers to a process whereby patient's T cells are extracted from a tumour biopsy or peripheral blood. These are then modified, expanded in vitro, and re-infused into the patient after host lymphodepletion. In BTC, the evidence for use of ACT is limited to case reports or small case series of patients treated in single-arm phase II studies.
A single case study of a patient with metastatic CCA treated with TILs after progression through multiple lines of chemotherapy was reported. This patient was recruited to a phase II study [41] where use of short-term cultured autologous TILs, following a lymphocyte-depleting regimen plus pembrolizumab, was tested. The patient was first treated with ACT, consisting of CD4 + erbb2 interacting protein (ERbB2IP) mutation-specific T cells, and this was then followed by IL-2 to enhance T-cell proliferation and function. After the treatment, all metastatic sites started to regress and a 30% partial response was seen at 7 months. The disease remained stable for 13 months. After this, some progression was seen in the lung metastases, whereas the liver metastases remained stable [42] .
In another case study, a 59-year-old patient with a diagnosis of locally advanced IHC received IL-2-activated T cells and a monoclonal antibody to CD3, 2 months post resection as an adjuvant therapy. After an immunological reaction was observed (skin reaction and raised peripheral blood lymphocytes), the patient was given the same immunotherapy every 3 months to maintain the response. At the time the case was reported, the patient was 3.5 years post-surgery without recurrence [43] .
Further to this case report, the same authors reported a casecontrol adjuvant study which investigated the use of autologous dendritic cell vaccine alongside activated T-cell transfer in patients who underwent curative surgery for IHC. 36 patients were treated with adjuvant adoptive transfer of T cells plus dendritic cell vaccine, and 26 patients were enrolled into the surgery only group. This study reported an improved OS of 31.9 months in the vaccinated group versus 17.4 months in the surgery only group (p = 0.022) [44] .
These case reports and small series suggest some activity for ACT in patients with advanced BTC.
Role of Immune Checkpoint Inhibitors in BTC
Programmed cell death ligand-1 (PD-L1) or B7 homologue 1 (B7-H1) is a ligand that binds to programmed death-1 receptor (PD-1), and their interaction can result in inhibition of T-lymphocyte survival, propagation, cytokine release, and cytotoxicity to escape the host cancer immune response [45] . Pembrolizumab, a humanised monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1, has received Food and Drug Administration (FDA) approval for melanoma, advanced and metastatic non-small cell lung cancer (NSCLC), metastatic head and neck squamous cell cancer, classical Hodgkin's lymphoma, and metastatic urothelial cancer. Expression of PD-L1 across various tumour types has been evaluated and correlated with poor prognosis, better prognosis, or no effect [46, 47] . A basket study which included various solid tumours, established the significance of PD-L1 expression in cancer cells as well as the tumour immune infiltrate as a predictive biomarker for response to PD-L1 inhibitors [48] . Table 1 summarises the clinical studies reporting expression of PD-L1 in BTC. Most studies have been done on IHC where up to 100% of cancer cells or immune cells show PD-L1 expression, although ranges are wide (as low as 29%). In patients with EHC, the ranges are much lower; whether this is a true difference or reflects the limitations of sample size and methodology is uncertain. Moreover, PD-L1 expression alone only provides a limited glimpse into immunocompetence. The interim results from the KEYNOTE-028 phase Ib clinical study for patients with BTC and PD-L1 expression ( 1%) treated with pembrolizumab reported an overall response rate of 17%, reasonable toxicity, and durable response (duration of treatment 40+ to 42+ weeks, when reported) [49] . The mature analysis and results of this study, expected to complete accrual in July 2018, are awaited.
Pembrolizumab was also approved by the FDA in May 2017 for the treatment of patients with metastatic or inoperable solid tumours with high microsatellite instability (MSI) or mismatch repair deficiency (MMR) [50] . One of the genetic risk factors for BTC includes Lynch syndrome, characterised by MSI and MMR deficiency [51] . The phase II study of pembrolizumab for treatment of cancers (CRC and other types) in 41 patients with and without MMR deficiency reported an immune-related PFS at 20 weeks of 78% in patients with MMR-deficient CRC, and of 67% in patients with MMR-deficient other cancers. In both the CRC (median follow-up 36 weeks) and other cancer types (median followup 21 weeks) with MMR deficiency, the median OS was not reached, whereas it was 5.0 months in patients with MMR-proficient CRC. This study reported exclusive response of MMR-deficient tumours to pembrolizumab when compared to MMR-proficient tumours, and it included 4 patients with CCA/ ampulla of Vater carcinoma amongst other cancer types [52] . A phase II basket study, which included 8 patients with BTC, evaluated the clinical efficacy of anti-PD1 antibody in advanced MMR-deficient tumours. An objective response rate of 53% and a complete response rate of 21% were achieved, and further analysis demonstrated that responding patients harboured vast amounts of mutation-associated neoantigens, making them susceptible to blockade by immune checkpoint inhibitors [53] . Thus, pembrolizumab may have clinical efficacy in patients with BTC with high MSI or MMR. 
Discussion
As immunotherapy is incorporated into the list of conventional anticancer treatments alongside surgery, chemotherapy, radiotherapy, and targeted treatments, there has been a trend for development of strategies to provide clinicians with tools to assess the efficacy of these treatments. Such models include the use of an immunoscore, cancer immunogram, PD-L1 expression, host microbiota, and tumour mutation burden (TMB), to name a few. Of these, the immunoscore (combined analysis of presence of CD8 + and CD45RO + in certain areas in a cancer) [54] has been validated as a prognostic tool for patient outcomes in resected CRC, but its application across other tumour types needs to be confirmed. Unlike immunoscore, the cancer immunogram, which consists of 7 key elements, is not yet a validated tool, but it acts as an initial framework for studying the interface between cancer and the immune system, and may predict the likelihood of response to checkpoint inhibitors [55] . Thus far, the expression of PD-L1 as reported by the KEYNOTE 001 study for NSCLC has been associated with clinical efficacy of agents that block the PD-L1 pathway. Nonetheless, its detection is not without limitations (differences in assays, intratumoural heterogeneity, variation in expression post treatments, and dynamic expression in space and time) [56] . The recent FDA approval for use of checkpoint inhibitors in other gastrointestinal (GI) malignancies includes HCC and CRC where they are effective irrespective of PD-L1 status, whereas in gastric or gastro-oesophageal junction cancer the approval is exclusively for patients with PD-L1-positive malignancies. This indicates that PD-1 expression is of limited predictive value for efficacy of checkpoint inhibitors in other GI cancers and leads clinicians and scientists to explore other possibilities to assess clinical efficacy for these newer agents.
More recently, further to PD-L1 expression, symbiotic microbial cells that constitute the human microbiome have emerged as components that may influence the clinical efficacy of PD-1 blockade. A study inspected the composition of baseline stool samples from 42 patients with metastatic melanoma, divided into 2 groups: responders and non-responders (similar characteristics). An association between certain bacterial species in the host gut flora and clinical response was seen in this study [57] .
Apart from PD-L1 expression and host microbiome, TMB is another host factor that has been investigated in relation to response to immune checkpoint inhibitors. A study evaluated 240 patients with advanced NSCLC to review differences between patients who had durable clinical benefit versus no benefit with immune checkpoint inhibitors by performing targeted next generation sequencing as well as whole exome sequencing. It was noted that TMB was higher in patients who had a durable clinical benefit (p = 0.006), suggesting its significance as a potential predictive marker [58] . Data for TMB in BTC is limited. Recent work from MD Anderson, which reviewed 309 patients with BTC, identified TMB of 6 mutations/Mb in 19.4% of cases [59] . They also reported that PIK3CA and DNA repair pathways might be associated with high TMB (defined at 20 mut/Mb), whereas high TMB was only found in 2.9% of cases, rendering BTC at the lower end of the spectrum for mutational load [59] . However, as response to immunotherapy is a complex, multifaceted phenomenon, this does not necessarily mean that BTC is precluded from the fast-growing list of cancers that may benefit from immune-mediated treatments.
Apart from the above discussed predictors of response, there are other avenues to consider. Conventionally, most of the patients recruited into phase I trials are patients with metastatic disease and exhibit a high tumour burden. This high burden suggests an active mechanism for host immune response evasion by the cancer cells. The role of high tumour burden and response to anti-PD-1 therapy was studied in patients with melanoma, particularly in stage IV disease. This trial highlighted an important issue that failure to induce an immune response in some patients was not due to a lack of immune activity but the imbalance between the high tumour burden and T-cell invigoration [60] . Whilst conducting trials in a metastatic setting in BTC, this issue might be hindering progression towards a positive signal of efficacy from immune-mediated therapies.
Immune-mediated treatments are now mainstream in a number of solid tumours. Understanding durability of responses, toxicity management, use in early stages (e.g., adjuvant), and mechanisms of resistance remain areas of investigation. There is no approved immunotherapy treatment for BTC yet, but the past few years have been enlightening and the list of cancers which are being treated with these agents is fast-growing and future research may eventually lead to the development of immunotherapy for poor-prognostic tumour types. Nonetheless, the multiple complex autonomous and extrinsic mechanisms that govern de-novo and acquired resistance [61] to immune-modulatory agents remain an avenue for future scientific exploration. Moreover, the value of these agents in conjunction with chemotherapy or radiotherapy which may alter the immunogenicity of solid tumours warrants further study.
Currently in BTC, studies of immunotherapeutic agents are ongoing and none of the current investigational drugs have been approved for this disease group. In order to achieve this, the basic immunology of BTC, the TME, and the role of immunosuppressive elements on immune cell function need to be better understood.
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